HC Wainwright Analysts Give Pacira Pharmaceuticals (PCRX) a $55.00 Price Target

Pacira Pharmaceuticals (NASDAQ:PCRX) has been given a $55.00 price target by research analysts at HC Wainwright in a research note issued on Thursday. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 18.66% from the stock’s previous close.

A number of other equities research analysts have also recently issued reports on PCRX. UBS Group initiated coverage on Pacira Pharmaceuticals in a research note on Wednesday, September 6th. They set a “market perform” rating on the stock. Oppenheimer initiated coverage on Pacira Pharmaceuticals in a research note on Thursday, September 7th. They set a “market perform” rating on the stock. CIBC initiated coverage on Pacira Pharmaceuticals in a research note on Thursday, September 7th. They set a “market perform” rating on the stock. Jefferies Group reiterated a “buy” rating and set a $59.00 price objective on shares of Pacira Pharmaceuticals in a research note on Thursday, September 7th. Finally, Mizuho reiterated a “buy” rating and set a $53.00 price objective on shares of Pacira Pharmaceuticals in a research note on Monday, September 25th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $49.00.

Pacira Pharmaceuticals (NASDAQ:PCRX) traded up $0.05 during midday trading on Thursday, reaching $46.35. The company’s stock had a trading volume of 1,064,500 shares, compared to its average volume of 928,800. The company has a market cap of $1,740.00, a PE ratio of -35.38 and a beta of 2.20. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.99 and a quick ratio of 6.24. Pacira Pharmaceuticals has a 12-month low of $29.81 and a 12-month high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings results on Wednesday, November 8th. The company reported $0.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The firm had revenue of $67.30 million for the quarter, compared to analysts’ expectations of $68.99 million. During the same quarter in the previous year, the business posted $0.20 EPS. The business’s quarterly revenue was down 1.6% compared to the same quarter last year. sell-side analysts forecast that Pacira Pharmaceuticals will post -0.85 earnings per share for the current fiscal year.

In other Pacira Pharmaceuticals news, Director Mark A. Kronenfeld bought 1,000 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The shares were acquired at an average cost of $41.60 per share, with a total value of $41,600.00. Following the acquisition, the director now owns 6,795 shares of the company’s stock, valued at $282,672. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO David M. Stack sold 58,885 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $38.34, for a total value of $2,257,650.90. Following the transaction, the chief executive officer now directly owns 159,164 shares in the company, valued at $6,102,347.76. The disclosure for this sale can be found here. Insiders have sold a total of 70,075 shares of company stock worth $2,707,452 over the last three months. 6.60% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of PCRX. Schwab Charles Investment Management Inc. grew its holdings in Pacira Pharmaceuticals by 8.5% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 178,700 shares of the company’s stock valued at $8,524,000 after buying an additional 13,973 shares in the last quarter. Rhumbline Advisers grew its holdings in Pacira Pharmaceuticals by 3.5% in the 2nd quarter. Rhumbline Advisers now owns 49,203 shares of the company’s stock valued at $2,347,000 after buying an additional 1,672 shares in the last quarter. SG Americas Securities LLC grew its holdings in Pacira Pharmaceuticals by 135.6% in the 2nd quarter. SG Americas Securities LLC now owns 6,395 shares of the company’s stock valued at $305,000 after buying an additional 3,681 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Pacira Pharmaceuticals by 5.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 218,087 shares of the company’s stock valued at $10,403,000 after buying an additional 11,652 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in Pacira Pharmaceuticals by 5.3% in the 2nd quarter. Legal & General Group Plc now owns 12,985 shares of the company’s stock valued at $620,000 after buying an additional 653 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: “HC Wainwright Analysts Give Pacira Pharmaceuticals (PCRX) a $55.00 Price Target” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2018/01/04/hc-wainwright-analysts-give-pacira-pharmaceuticals-pcrx-a-55-00-price-target.html.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply